Estetrol – a new stage of combined hormonal contraception

DOI

https://dx.doi.org/10.18565/aig.2023.72

Apolikhina I.A., Prilepskaya V.N., Gorbunova E.A., Mezhevitinova E.A., Bychkova A.E.
1) Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia; 2) Department of Obstetrics, Gynecology, Perinatology, and Reproductology, .Institute for Advanced Postgraduate Trainining, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia, Moscow, Russia

The paper analyzes the modern literature data on estetrol, a native fetal estrogen that has been proposed as an estrogen component in the combined oral contraceptives, where only ethynyl estradiol has been traditionally used. a number of preclinical and clinical trials have provided evidence that estetrol is an estrogen that has unique properties since it does not affect hepatic parameters and hemostasis, has an antiestrogen effect on breast tissue and in high doses demonstrates an antitumor effect in breast and prostate cancers. Due to the above properties, estetrol has become an estrogen that become potentially safe as a component of the combined oral contraceptive containing 15 mg of estetrol and 3 mg of drospirenon in one tablet to be used in the 24/4 regimen, which have been now completed and shown the high efficacy of the contraceptive agent, as well as due to the minimal side effects: a good patient compliance with its usage. All phases of clinical trials of the new combined hormonal contraceptive containing 15 mg of estetrol and 3 mg of drospirenone in one tablet to be used in the 24/4 regimen, which have now been completed and shown the high efficacy of the contraceptive agent, a high safety, as well as due to the minimal side effects: a good patient compliance with its usage. Phase III trials of the new combined hormonal contraceptive, which have now been completed and shown that the new agent esterette is already available for patients and physicians.
Conclusion: The new hormonal combined oral contraceptive with a fetal estrogen, estetrol in combination with drispirenone ensures effective contraception, predictable presentations of hemorrhage, and a favorable safety profile.

Authors' contributions: Apolikhina I.A. – concept and design of the review; Apolikhina I.A., Gorbunova E.A. – material collection, processing and analysis, writing the text; Apolikhina I.A., Gorbunova E.A., Prilepskaya V.N., Mezhevitinova E.A., Bychkova A.E. – editing the article.
Conflicts of interest: The authors declare that there are no conflicts of interest.
Funding: The investigation has not been sponsored.
For citation: Apolikhina I.A., Prilepskaya V.N., Gorbunova E.A., Mezhevitinova E.A.,
Bychkova A.E. Estetrol – a new stage of combined hormonal contraception.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2023; (3): 134-140 (in Russian)
https://dx.doi.org/10.18565/aig.2023.72

contraception

combined hormonal contraception

combined oral contraceptives

estetrol

sexual hormones

hemostasis

metabolism

drospirinone

native estrogen

estrogen safety

estrogens

thrombosis

breast

breast cancer

Perl index

Full text (in Russian)

Прилепская В.Н., Межевитинова Е.А., Назарова Н.М., Якушевская О.В., Аганезова Н.В., Чернуха Г.Е., Кепша М.А. Национальные медицинские критерии приемлемости методов контрацепции (2022): вклад в охрану репродуктивного здоровья женщин. Акушерство и гинекология: новости, мнения, обучение. 2022; 10(4): 53-60. [Prilepskaya V.N., Mezhevitinova E.A., Nazarova N.M., Yakushevskaya O.V., Aganesova N.V., Chernukha G.E., Kepsha M.A. New national medical acceptance criteria for methods of contraception (2022): contribution to women’s reproductive health. Obstetrics and Gynecology: News, Opinions, Training. 2022; 10(4): 53-60. (in Russian)]. https://dx.doi.org/10.33029/2303-9698-2022-10-4-53-60.
United Nations, Department of Economic and Social Affairs, Population Division. Contraceptive use by method 2019: data booklet (ST/ESA/SER.A/435). 2019.
Sturtevant R. Long-term experience with Enovid among clinic patients: results after 2 1/2 to 6 years of individual patient use. J. Reprod. Med. 1970; 5(2): 90-5.
Dragoman M.V. The combined oral contraceptive pill -- recent developments, risks and benefits. Best Pract. Res. Clin. Obstet. Gynaecol. 2014; 28(6): 825-34. https://dx.doi.org/10.1016/j.bpobgyn.2014.06.003.
Oelkers W.H.K. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric. 2005; 8(Suppl. 3): 19-27. https://dx.doi.org/10.1080/13697130500330341.
Valera M.C., Fontaine C., Dupuis M., Noirrit-Esclassan E., Vinel A., Guillaume M. et al. Towards optimization of estrogen receptor modulation in medicine. Pharmacol. Ther. 2018; 189: 123-9. https://dx.doi.org/10.1016/j.pharmthera.2018.05.002.
Arnal J.-F., Lenfant F., Metivier R., Flouriot G., Henrion D., Adlanmerini M. et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol. Rev. 2017; 97(3): 1045-87.https://dx.doi.org/10.1152/physrev.00024.2016.
Deroo B.J., Korach K.S. Estrogen receptors and human disease. J. Clin. Invest. 2006; 116(3): 242-6. https://dx.doi.org/10.1172/JCI27987.
Сметник А.А., Родионов В.В., Кометова В.В., Бурменская О.В., Дардык М.В., Сенча А.Н., Ермакова Е.И., Ашрафян Л.А. Молочная железа и половые гормоны. Акушерство и гинекология. 2021; 12: 58-66. [Smetnik A.A., Rodionov V.V., Kometova V.V., Burmenskaya O.V., Dardyk M.V., Sencha A.N., Ermakova E.I., Ashrafyan L.A. The breast and sex hormones. Obstetrics and Gynecology. 2021; (12): 58-66. (in Russian)]. https://dx.doi.org/10.18565/aig.2021.12.58-66.
Tulchinsky D., Frigoletto F.D. Jr, Ryan K.J., Fishman J. Plasma estetrol as an index of fetal well-being. J. Clin. Endocrinol. Metab. 1975; 40(4): 560-7.https://dx.doi.org/10.1210/jcem-40-4-560.
Bastianelli C., Farris M., Rosato E., Brosens I., Benagiano G. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism. Expert Rev. Clin. Pharmacol. 2017; 10(3): 315-26. https://dx.doi.org/10.1080/17512433.2017.1271708.
Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005; 8(Suppl. 1): 3-63.https://dx.doi.org/10.1080/13697130500148875.
Hagen A., Barr M. Metabolism of 17β-oestradiol-4-14C in early infancy. Acta Endocrinol. (Copenh.). 1965; 49: 207-20.
Fruzzetti F., Fidecicchi T., Montt Guevara M.M., Simoncini T. Estetrol: a new choice for contraception. J. Clin. Med. 2021; 10(23): 5625.https://dx.doi.org/10.3390/jcm10235625.
Holinka C.F., Diczfalusy E., Coelingh Bennink H.J. Estetrol: a unique steroid in human pregnancy. J. Steroid Biochem. Mol. Biol. 2008; 110(1-2): 138-43. https://dx.doi.org/10.1016/j.jsbmb.2008.03.027.
Warmerdam E.G.J.C., Visser M., Coelingh Bennink H.J.T., Groen M. A new route of synthesis of estetrol. Climacteric. 2008; 11(Suppl. 1): 59-63.https://dx.doi.org/10.1080/13697130802054078.
Visser M., Holinka C.F., Coelingh Bennink H.J.T. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women. Climacteric. 2008; 11(Suppl. 1): 31-40. https://dx.doi.org/10.1080/13697130802056511.
Gérard C., Mestdagt M., Tskitishvili E., Communal L., Gompel A., Silva E. et al. Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. Oncotarget. 2015; 6(19): 17621-36. https://dx.doi.org/10.18632/oncotarget.4184.
Schmidt M., Lenhard H., Hoenig A., Zimmerman Y., Krijgh J., Jansen M., Coelingh Benninket H.J.T. Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. J. Cancer Res. Clin. Oncol. 2021; 147(6): 1833-42. https://dx.doi.org/10.1007/s00432-020-03472-8.
Coelingh Bennink H.J.T., Van Moorselaar J.A., Crawford E.D., Roos E.P.M., Somford D.M., Roeleveld T.A. et al. Estetrol cotreatment of androgen deprivation therapy in infiltrating or metastatic, castration-sensitive prostate cancer: a randomized, double-blind, phase II trial (PCombi). Eur. Urol. Open Sci. 2021; 28: 52-61. https://dx.doi.org/10.1016/j.euros.2021.04.005.
Estetra S.P.R.L. A randomized double-blind placebo controlled phase 3 trial to evaluate the efficacy and safety of estetrol for the treatment of moderate to severe vasomotor symptoms in postmenopausal women (E4Comfort Study I, II). EUDRACT 2019-001289-14. Clinicaltrials.gov NCT04209543, Clinicaltrials.Gov NCT04090957.
Gemzell-Danielsson K., Apter D., Zatik J., Weyers S., Piltonen T., Suturina L. et al. Estetrol-drospirenone combination oral contraceptive: a clinical study of contraceptive eficacy, bleeding pattern and safety in Europe and Russia. BJOG. 2022; 129(1): 63-71. https://dx.doi.org/10.1111/1471-0528.16840.
Creinin M.D., Westhoff C.L., Bouchard C., Chen M.J., Jensen J.T., Kaunitz A.M. et al. Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. Contraception. 2021; 104(3): 222-8.https://dx.doi.org/10.1016/j.contraception.2021.05.002.
Morimont L., Dogne J.M., Douxfils J. Letter to the editors-in-chief in response to the article of Abou-Ismail, et al. Entitled “estrogen and thrombosis: a bench to bedside review. Thromb. Res. 2020; 193: 221-3. https://dx.doi.org/10.1016/j.thromres.2020.08.006.
Morimont L., Jost M., Gaspard U., Foidart J.M., Dogné J.M., Douxfils J. Low thrombin generation in users of a contraceptive containing estetrol and drospirenone. J. Clin. Endocrinol. Metab. 2022; 108(1): 135-43.https://dx.doi.org/10.1210/clinem/dgac511.
Mawet M., Maillard C., Klipping C., Zimmerman Y., Foidart J.M., Coelingh Bennink H.J.T. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur. J. Contracept. Reprod. Health Care. 2015; 20(6): 463-75. https://dx.doi.org/10.3109/13625187.2015.1068934.
Gallez A., Blacher S., Maquoi E., Konradowski E., Joiret M., Primac I. et al. Estetrol combined to progestogen for menopause or contraception indication is neutral on breast cancer. Cancers (Basel). 2021; 13(10): 2486.https://dx.doi.org/10.3390/cancers13102486.
Lee A., Syed Y.Y. Estetrol/drospirenone: a review in oral contraception. Drugs. 2022; 82(10): 1117-25. https://dx.doi.org/10.1007/s40265-022-01738-8. Erratum in: Drugs. 2022; 82(12): 1341.
Сутурина Л.В., Дикке Г.Б. Опыт применения у молодых женщин низкодозированной левоноргестрел-содержащей внутриматочной системы LCS16 и комбинированного орального контрацептива, содержащего 30 мкг этинилэстрадиола и 3 мг дроспиренона. Акушерство и гинекология. 2021; 11: 230-6. [Suturina L.V., Dikke G.B. Experience in the use of low-dosed levonorgestrel-containing intrauterine system LCS16 and combined oral contraceptive containing 30 mcg ethinyl estradiol and 3 mg drospirenone in young women. Obstetrics and Gynecology. 2021; (11): 230-6. (in Russian)]. https://dx.doi.org/10.18565/aig.2021.11.230-236.

Received 17.03.2023

Accepted 20.03.2023

Inna A. Apolikhina, Dr. Med Sci., Professor, Head of the Department of Aesthetic Gynecology and Rehabilitation, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; Professor of the Department of Obstetrics, Gynecology, Perinatology, and Reproductology, Institute
of Professional Education, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia; Member of the Board of the Russian Society of Obstetricians and Gynecologists; President of the Association of Aesthetic Gynecology Specialists (AAGS), +7(495)735-10-55, i_apolikhina@oparina4.ru,
https://orcid.org/0000-0002-4581-6295, 4, Akademika Oparina str., Moscow, 117997, Russia.
Vera N. Prilepskaya, Dr. Med. Sci., Professor, Honored Scientist of the Russian Federation, Head of the Scientific Polyclinic Department, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, vprilepskaya@mail.ru, https://orcid.org/0000-0003-3993-7629,
4 Akademika Oparina str., Moscow, 117997, Russia.
Elena A. Gorbunova, Obstetrician-gynecologist, Researcher, Department of Aesthetic Gynecology and Rehabilitation, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, +7(495)735-10-55, el_gorbunova@oparina4.ru,
https://orcid.org/0000-0002-4723-4299, 4, Akademika Oparina str., Moscow, 117997, Russia.
Elena A. Mezhevitinova, Ph.D, Leading Researcher at the Scientific and Polyclinic Department, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, mejevitinova@mail.ru, https://orcid.org/0000-0003-2977-9065, 4 Akademika Oparina str., Moscow, 117997, Russia.
Anastasia E. Bychkova, obstetrician-gynecologist at the Department of Aesthetic Gynecology and Rehabilitation V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, a_bychkova@oparina4.ru, https://orcid.org/0000-0003-4855-81-88,
4 Akademika Oparina str., Moscow, 117997, Russia.

Estetrol – a new stage of combined hormonal contraception

Apolikhina I.A., Prilepskaya V.N., Gorbunova E.A., Mezhevitinova E.A., Bychkova A.E.

Keywords

References

About the Authors

Similar Articles